跳至主要内容
临床试验/NCT03286205
NCT03286205撤回4 期

A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.

Sutter Gould Medical Foundation1 个研究点 分布在 1 个国家开始时间: 2015年4月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
试验地点
1
主要终点
superior dosing regimen exists for INfed

研究概览

简要总结

The purpose of this study is to establish which dosing schedule of INfed (Iron dextrose) is superior for the treatment of iron deficient anemia.

详细描述

The purpose of this study is to establish which dosing schedule of INfed (Iron dextrose) is superior for the treatment of iron deficient anemia. The two dosing regimens under review are a low dose weekly or a larger dose given every three weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients over the age of 18 years old.
  • Being treated by a Sutter Health Physician.
  • Hemoglobin of < 10mg/dl for Men and Women
  • Ferritin </= 10ng/ml
  • Patients in whom oral administration is unsatisfactory or impossible.

排除标准

  • Patients with a history of receiving iron or other hematinic in the preceding 3 months, oral iron is allowable.
  • Anemia due to acute blood loss; menorrhagia is allowed.
  • Patients with a current illness known to interact with iron status.
  • Patients unwilling to consent to required blood draws.
  • Patients who are viewed as unable to complete treatment, based on PI recommendation.

研究组 & 干预措施

Weekly Dosage

Active Comparator

weekly dose of 100mg

干预措施: IV iron (Drug)

3 week dosage

Active Comparator

every 3 week dosage.

干预措施: IV iron (Drug)

结局指标

主要结局

superior dosing regimen exists for INfed

时间窗: 3 years

shown by a 2gm/dl increase in HgB

High Dose Effect

时间窗: 3 years

INfed can be given at high dose without an increase in AE and/or SAEs frequency

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

David Adkins

Principal Investigator

Sutter Gould Medical Foundation

研究点 (1)

Loading locations...

相似试验